Abstract:Primary Membranous Nephropathy is an autoimmune disease caused by the deposition of Immunoglobulin G and complement components on the subepithelial layer of the glomerular capillary wall. It affects 5-10 patients per million population and is the second cause of nephrotic syndrome in adults after diabetic kidney disease. For decades steroids and non-specific immunosuppressive medications have been advocated as a therapeutic option for patients with membranous nephropathy at increased risk of kidney failure because of persistent nephrotic syndrome. These medications, however, have major and potentially fatal adverse effects that offset their potential benefits and should be abandoned. The discovery of nephritogenic autoantibodies against podocyte M-type phospholipase A2 receptor (PLA2R) and thrombospondin type-1 domain-containing protein 7A (THSD7A) antigens provided a clear pathophysiological rationale for interventions specifically targeting B cell lineages to prevent antibody production and subepithelial deposition. The first-in-class anti-CD20 monoclonal antibody rituximab is safe and achieves remission in approximately two-thirds of patients with nephrotic membranous nephropathy. In PLA2R-related disease, remission is invariably preceded by depletion of anti PLA2R autoantibodies and relapse by their re-emergence into the circulation. Because of its superior risk/benefit profile as compared to non-specific immunosuppressive therapy, rituximab is now first-line therapy for patients with membranous nephropathy at risk of kidney failure. Novel monoclonal antibodies targeting CD20 cells (such as ofatumumab and obinutuzumab) and their differentiation (belimumab) or targeting long-living antibody producing CD38 memory cells (daratumumab, felzartamab) along with proteasome inhibitors such as bortezomib are being evaluated for the treatment of nephrotic patients with membranous nephropathy who are resistant or intolerant to rituximab. Complement inhibitor therapy might serve to stop the glomerular inflammatory process until the benefits of these medications become effective. Thus, major advances in the understanding of the mechanisms of membranous nephropathy have led to novel treatment perspectives. The integrated evaluation of serum autoantibody titer and proteinuria, together with serum albumin levels in patients with overt nephrotic syndrome, could guide diagnosis of membranous nephropathy and individually tailored treatment protocols. The introduction of monoclonal antibodies targeting disease-specific mechanisms will pave the way for a novel therapeutic paradigm based on the principle of precision medicine and personalized therapy.

Therapeutic Monoclonal Antibody Therapies in Chronic Autoimmune Demyelinating Neuropathies

Autoimmune diseases of the peripheral nervous system

Antibodies in Autoimmune Neuropathies: What to Test, How to Test, Why to Test

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): Current Therapies and Future Approaches.

Autoimmune Peripheral Neuropathies and Contribution of Antiganglioside/Sulphatide Autoantibody Testing

B cells as therapeutic targets in autoimmune neurological disorders

Immune mechanisms, the role of complement, and related therapies in autoimmune neuropathies

CIDP trials and tribulations

[Pathomechanism Underlying Intravenous Immunoglobulin Therapy for Chronic Inflammatory Demyelinating Polyneuropathy]

Disease-modifying treatments for neuromyelitis optica spectrum disorder in the context of a new generation of biotherapies

Monoclonal Antibody-Based Treatments for Neuromyelitis Optica Spectrum Disorders: from Bench to Bedside

Autoantibodies in immune-mediated inflammatory neuropathies

Neurologic diseases of the central nervous system with pathophysiologically relevant autoantibodies--perspectives for immunoadsorption

Novel therapies in CIDP

The Role of Chimeric Antigen Receptor T‐Cell Therapy in Immune‐Mediated Neurological Diseases

Disease-Specific Treatment For Primary Membranous Nephropathy: The Role of Monoclonal Antibodies

Efficacy and Safety of Monoclonal Antibodies in Neuromyelitis Optica Spectrum Disorders: A Survival Meta-Analysis of Randomized Controlled Trials

Therapeutic Approach to Autoimmune Neurologic Disorders

Favorable long-term outcomes of autoimmune nodopathy with mycophenolate mofetil

Antibody Therapies in Autoimmune Inflammatory Myopathies: Promising Treatment Options

Chimeric antigen receptor T-cell therapy for autoimmune diseases of the central nervous system: a systematic literature review